Respiratory safety of lemborexant in adult and elderly subjects with moderate-to-severe chronic obstructive pulmonary disease.

J Sleep Res · 2025 · PMC11911032 · PMID 39266012

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

did not reach statistical significancep = 0.056so close (0.05 < p ≤ 0.1)

After multiple doses (Day 8), WASO was numerically lower with LEM10 treatment compared with PBO, although this difference did not reach statistical significance (LSM [SE], LEM10: 90.4 [9.9] min; PBO: 106.1 [9.9] min; p = 0.056; Figure 2c ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.